Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Return on Capital Employed (2016 - 2026)

Anika Therapeutics has reported Return on Capital Employed over the past 16 years, most recently at 7.48% for Q1 2026.

  • Quarterly Return on Capital Employed fell 363.0% to 7.48% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 7.48% through Mar 2026, down 363.0% year-over-year, with the annual reading at 6.33% for FY2025, 394.0% down from the prior year.
  • Return on Capital Employed was 7.48% for Q1 2026 at Anika Therapeutics, down from 6.58% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 9.17% in Q3 2024 and troughed at 7.48% in Q1 2026.
  • The 5-year median for Return on Capital Employed is 2.48% (2023), against an average of 1.8%.
  • Year-over-year, Return on Capital Employed skyrocketed 1165bps in 2024 and then tumbled -1648bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 1.15% in 2022, then tumbled by -73bps to 0.31% in 2023, then plummeted by -937bps to 2.63% in 2024, then tumbled by -150bps to 6.58% in 2025, then decreased by -14bps to 7.48% in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Return on Capital Employed are 7.48% (Q1 2026), 6.58% (Q4 2025), and 7.32% (Q3 2025).